Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease

Historically cirrhosis has been considered as the prototype of acquired bleeding disorders. More recently, however, it has become clear that the hemostatic profile in patients with cirrhosis is in a new and fragile balance due to the concomitant decline in pro- and antihemostatic pathways [1]. This fragile balance can easily lead to bleeding or thrombotic events. Treatment of thrombotic complications in patients with cirrhosis is complicated by multiple factors related to cirrhosis-associated coagulopathy.

Source: Thrombosis Research - December 13, 2016 Category: Hematology Authors: Sarah Bos, Wilma Potze, Mohammad S. Siddiqui, Sherry L. Boyett, Jelle Adelmeijer, Kalyani Daita, Ton Lisman, Arun J. Sanyal Tags: Correspondence Source Type: research